Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2018 - 2025)

Protalix BioTherapeutics (PLX) has 4 years of Long-Term Deferred Tax data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax fell 6.2% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 6.2%, while the annual FY2024 figure was $2.9 million, 7.63% down from the prior year.
  • Long-Term Deferred Tax reached $2.7 million in Q3 2025 per PLX's latest filing, down from $2.7 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $3.3 million in Q2 2024 and bottomed at $2.7 million in Q3 2025.
  • Average Long-Term Deferred Tax over 3 years is $3.0 million, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: increased 5.4% in 2024, then dropped 17.01% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $3.1 million in 2023, then dropped by 7.63% to $2.9 million in 2024, then fell by 6.2% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $2.7 million in Q3 2025, $2.7 million in Q2 2025, and $3.0 million in Q1 2025.